Global priorities for research and the relative importance of different research outcomes: an international Delphi survey of malaria research experts by Mulligan, J & Conteh, L
Mulligan and Conteh  Malar J  (2016) 15:585 
DOI 10.1186/s12936-016-1628-4
RESEARCH
Global priorities for research and the 
relative importance of different research 
outcomes: an international Delphi survey 
of malaria research experts
Jo‑Ann Mulligan1,2*  and Lesong Conteh2
Abstract 
Background: As global research investment increases, attention inevitably turns to assessing and measuring the 
outcomes and impact from research programmes. Research can have many different outcomes such as producing 
advances in scientific knowledge, building research capacity and, ultimately, health and broader societal benefits. 
The aim of this study was to test the use of a Delphi methodology as a way of gathering views from malaria research 
experts on research priorities and eliciting relative valuations of the different types of health research impact.
Methods: An international Delphi survey of 60 malaria research experts was used to understand views on research 
outcomes and priorities within malaria and across global health more widely.
Results: The study demonstrated the application of the Delphi technique to eliciting views on malaria specific 
research priorities, wider global health research priorities and the values assigned to different types of research 
impact. In terms of the most important past research successes, the development of new anti‑malarial drugs and 
insecticide‑treated bed nets were rated as the most important. When asked about research priorities for future fund‑
ing, respondents ranked tackling emerging drug and insecticide resistance the highest. With respect to research 
impact, the panel valued research that focuses on health and health sector benefits and informing policy and product 
development. Contributions to scientific knowledge, although highly valued, came lower down the ranking, sug‑
gesting that efforts to move research discoveries to health products and services are valued more highly than pure 
advances in scientific knowledge.
Conclusions: Although the Delphi technique has been used to elicit views on research questions in global health 
this was the first time it has been used to assess how a group of research experts value or rank different types of 
research impact. The results suggest it is feasible to inject the views of a key stakeholder group into the research pri‑
oritization process and the Delphi approach is a useful tool for eliciting views on the value or importance of research 
impact. Future work will explore other methods for assessing and valuing research impact and test the feasibility of 
developing a composite tool for measuring research outcomes weighted by the values of different stakeholders.
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Background
The last decade has seen increased attention to assess-
ment and measurement of outcomes from research [1–
6]. Research can have many different types of impact, 
including producing advances in scientific knowledge 
(through the production of papers and other published 
outputs, etc.), building research capacity, production of 
new products and devices, through to changes in pol-
icy, and ultimately health and societal gains. Funders 
of research are increasingly interested in methods for 
describing and quantifying these returns as well as gain-
ing a better understanding of the different kinds of ben-
efit or ‘payback’ from research outcomes [7]. As yet there 
is no agreed balance between the different dimensions 
of global health research output and no agreed generic 
measure of research performance that indicates whether 
one research project or programme has greater impact 
than another, or whether one set of research performance 
indicator values can be judged unequivocally to be an 
improvement on the results of previous years. Moreover, 
whilst there is a growing toolbox of methods for assessing 
and quantifying research impact, there is relatively little 
information on how different stakeholders value or pri-
oritize the various outcomes of global health research. If 
development and research funding agencies wish to bet-
ter understand how to maximize the outcomes of global 
health research, a first step is to better understand how 
different stakeholders value or rank the different out-
comes from research.
The key to examining how people assess different 
research outcomes is to address the essentially subjec-
tive nature of the ‘trade-offs’ and to elicit how various 
stakeholders rank or prioritize outcomes from research. 
Stakeholders potentially include research funders, policy 
makers and the public, who are the ultimate ‘beneficiar-
ies’ of research. Another important stakeholder group 
is the researchers themselves who not only ‘produce’ 
research, but through peer review, assess research out-
comes, set research priorities and are themselves impor-
tant users of the immediate outputs of research [8].
Study objective
To understand views on research outcomes and priori-
ties within malaria and across global health more widely, 
an international online Delphi survey of malaria research 
experts was conducted. The specific objectives of this 
study were to:
1. Contribute to the methodological literature on the 
assessment of research impact by applying the Del-
phi technique to the analysis of relative valuations of 
research outcomes;
2. Elicit rankings or values on different research out-
comes;
3. Elicit rankings on research priorities within malaria 
and global health research.
The overall eventual aim (and the subject of future 
research) is to use the judgements on research outcomes 
to develop and test a methodological framework for 
assessing the impact of research investments of global 
health research.
Methods
The Delphi method
The Delphi process is a method by which input from 
individuals are elicited using a systematic, anonymous 
iterative approach [9]. The goal is to arrive at consensus 
around the topic in question.
The process works through a series of structured 
questionnaires (commonly referred to as ‘rounds’). 
The questionnaires are completed anonymously by 
‘experts’ (commonly referred to as the panellists, par-
ticipants or respondents). In the first round, the Delphi 
approach typically begins with an open-ended question-
naire to help set the parameters of the inquiry and iden-
tify which issues are of most importance to participants 
and researchers. In the second round each participant 
receives a second questionnaire and is asked to review 
the collated results from the first round. Participants 
are typically asked to rate or rank-order items to estab-
lish the relative importance among the different issues. 
As a result of round 2, areas of consensus and potential 
disagreement are identified. The Delphi process always 
involves at least two rounds but can extend to four or 
more rounds depending on the topic complexity. Impor-
tantly, the feedback process inherent in the Delphi tech-
nique allows and encourages the selected participants 
to re-assess their initial judgements about the informa-
tion provided in previous iterations [10]. This gives the 
researchers more scope to follow up for clarification and 
further qualitative data [11]. Responses from panellists 
are always anonymous to everyone except the researcher. 
Finally, the Delphi group size does not depend on statisti-
cal power, but rather on group dynamics for arriving at 
consensus among experts. In this study the Delphi pro-
cess was applied to invite expert opinions on the value of 
different types of research outcomes and research priori-
ties in malaria and global health.
Delphi surveys have become a well-established tech-
nique for gathering expert opinions [12]. For instance, 
Fisk and colleagues used a Delphi exercise to assess 
absolute and relative government and charitable fund-
ing for maternal and peri-natal research in the UK and 
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internationally [13]. In another study Fehr et al. employed 
an expert Delphi survey technique to examine and under-
stand experts’ opinions on causes for lack of treatment 
options for neglected diseases and on feasible measures 
to promote research and development [14]. The survey 
also elicited expert opinions on the desirability of a regu-
latory instrument to promote research and development 
for neglected diseases. The Delphi approach has also 
been used to reach consensus on key parameters for pub-
lic health and economic models relating to the outcome 
of untreated febrile illnesses [15].
Study population
Panellists for the study were purposively selected based 
on their expertise and international reputation in malaria 
research, their involvement in the global malaria policy 
process and their relevant publications in the clinical and 
public health literature. The study aimed for a spread of 
experience from Europe, the USA, west, east, central and 
southern Africa and south and southeast Asia.
Survey tool development
As a formative step, a half-day workshop was conducted 
with research leaders and experts in the field to develop 
broad questions to address global research priorities. 
This formed part of a wider public consultation process 
to assess research priorities [16]. To elicit views on the 
relative importance of different kinds of research outputs, 
a desk review of the various types of research impact 
and the models for classifying them was conducted. The 
review revealed a variety of theoretical frameworks and 
methodological approaches including, bibliometrics [2, 
5, 6, 17]; so-called ‘payback’ and other multi-dimensional 
approaches [2, 4, 5]; economic approaches [1, 17]; and, 
case study approaches [2, 4, 6]. The payback framework 
was selected as the initial basis for eliciting views because 
it is multi-dimensional and very similar to the ways in 
which many research funders classify research output 
[18]. The payback framework is based around five cate-
gories of research impact: (a) knowledge production; (b) 
benefits for future research and research use; (c) inform-
ing policy and product development; (d) health sector 
benefits; and, (e) broader economic benefits (Box 1).
Box  1 The payback approach to  classifying the different 
outcomes from research
Category descriptions
Contribution to knowledge e.g., the initial academic outputs from research 
such as journal articles; conference presentations; book chapters, and 
research reports
Benefits to future research and research use e.g., better targeting of future 
research; building research capacity in developing countries; other 
educational benefits
Category descriptions
Benefits from informing policy and product development e.g., improved 
information bases for decision making; development of new drugs, 
vaccines, and other technologies
Health and health sector benefits e.g., improvements in health; improve‑
ments in the effectiveness and delivery of existing services
Broader economic benefits e.g., wider economic benefits from commercial 
exploitation of innovations arising from R&D; economic benefits from a 
healthy workforce
The framework was originally developed to examine 
the impact of UK health services research [18]. It was 
subsequently extended to examine basic and early clini-
cal biomedical research [19, 20]. While the framework 
has been used to assess the impact of health research in 
the UK and North America, it has not been used widely 
to capture outcomes from global health or development 
research. Thus, a secondary aim of the study is to gain 
consensus on whether these are appropriate outcome 
categories or whether there are more appropriate catego-
ries of research outcome to consider.
Survey process and content
The Delphi process followed the usual principles of 
anonymity, feedback and iteration [9]. The survey was 
conducted online in two rounds using Qualtrics online 
survey software [21]. Each expert received an individual 
email with a unique survey link to the questionnaire. This 
allowed follow-up with non-respondents. Respondents 
were sent two personalized reminders before the survey 
deadline. See Annex 1 for the full set of questions asked. 
Ethical approval for the study was obtained from the 
Imperial College Research Ethics Committee.
Round 1 Invited experts were sent the round 1 ques-
tionnaire with an email cover letter in March 2015 and 
were given four weeks to complete the survey. The ques-
tionnaire began by asking respondents for their views on 
the most important malaria research developments in the 
last 20 years, then the most important malaria research 
priorities in the next 20  years and finally the top global 
health issues in the next 20–50 years.
To assess the relative importance of different types of 
research outcomes, the payback framework category 
descriptions were refined to ensure they were easy to 
interpret by the panel participants. Respondents were then 
asked to assign a percentage weight to each category, with 
the total summing to 100. This would force respondents 
to trade-off between the different categories. The ques-
tionnaire also invited respondents to make suggestions on 
whether to add or amend any of the existing categories.
Finally, panellists were asked to provide feedback on 
the survey structure and questions and basic demo-
graphic information, including location, area of work 
Page 4 of 12Mulligan and Conteh  Malar J  (2016) 15:585 
and years of relevant work or research experience were 
also collected. At the end of the first round, survey par-
ticipants were informed that their results would be col-
lated and fed back to them in a second round, where they 
would have the opportunity to revise their opinions if 
they so wished.
Round 2 Experts that replied to the first round were 
sent a second questionnaire in June 2015 with three 
weeks to complete the survey. The questionnaire sum-
marized the results from the first round and participants 
were invited to modify their responses in the light of the 
anonymized group responses. The format for the second 
round differed from the first round in that panellists were 
asked to indicate how important they considered each of 
the developments identified in the first round on a five-
point ‘Likert’ scale: from ‘most important’, ‘important’, 
‘less important’, ‘least important’, to ‘no judgement’. Par-
ticipants were able to rank more than one issue in the top 
ten issues presented as ‘most important’. The use of the 
Likert scale as opposed to free text responses was cho-
sen in the second round because the responses are easily 
quantifiable and the technique is readily understandable 
by participants [22]. Another advantage of Likert scales 
over free text responses is they enable respondents to 
respond in degrees of agreement (which makes answer-
ing questions easier) as well as to allow for undecided 
or neutral feelings about the topic of interest [23]. The 
introduction letter to participants and survey tools are 
provided in Additional File 1.
Results
Participation, attrition and demographic data
Of the 103 malaria research experts originally contacted, 
60 (58%) initially agreed to participate and completed 
the first questionnaire, and 49 experts (48.5%) completed 
both the first and second round questionnaire (Fig.  1). 
Professional affiliations of malaria research experts in 
both rounds were similar with the majority of participants 
working in an academic environment (Round 1: 56.7%; 
Round 2: 59.2%) (Fig.  2). Residency of participants was 
also similar in both rounds with most participants indi-
cating their place of residence in a high-income country 
(Round 1: 51.7%; Round 2: 55.1%) (Fig. 3). Most partici-
pants had more than 20  years’ relevant work experience 
in both rounds (Round 1: 55.0%; Round 2: 57.1%) (Fig. 4).
The first question asked for views on the most impor-
tant research developments in the last 20  years. In the 
first round, these were free text responses and partici-
pants were invited to list up to three separate develop-
ments. The responses were then coded and categorized. 
In the second round, the top ten research developments 
from the first round were presented back to experts in 
order of importance (i.e., percentage mentioning as a 
top-three issue). Experts were then asked to indicate how 
important they considered each development to be on a 
five-point scale: ‘most important’, ‘important’, ‘less impor-
tant’, ‘least important’, and ‘no judgement’ (Fig. 5).
The development of new drugs for malaria and insec-
ticide-treated nets were the top two most important 
developments in malaria research in both the first and 
second round. Although the question was focused on 
research developments, many experts in the first round 
cited the importance of increased funding for malaria 
control more generally as an important influence on 
research. This was confirmed in the second round with 
29 (60.4%) experts mentioning it as ‘most important’. The 
survey also asked respondents (in the first round only) to 
tell us what ‘surprised’ them most about developments in 
malaria research in the last 20 years. These were free text 
responses to add qualitative context to the earlier ques-
tion on what they considered to be the most important 
past developments within malaria research. This elicited a 
wide range of responses covering many different themes. 
The theme most frequently mentioned by respondents 
was the failure to develop an effective malaria vaccine 
with ten out of the 60 respondents referencing it some 
Drops out at each stage
No. originally contacted 103
43 
Took part in 1st round 60
11 
Took part in 1st and 2nd round 49
Fig. 1 Respondents/non‑respondents at each stage of the process
56.7% 59.2%
11.7%
14.3%
1.7%
2.0%11.7%
12.2%
6.7%
8.2%11.7%
4.1%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Round 1 (N=60) Round 2 (N=49)
Not stated
Other
NGO
Internaonal organisaon
Naonal govt. 
Academia
Fig. 2 Professional affiliation of participants
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way. Other themes included the speed in progress in 
reducing malaria mortality from the deployment of exist-
ing tools (eight respondents) and the lack of investment 
and innovation in vector control research (six respond-
ents). Box  2 shows a selection of comments that cap-
ture the variety of free text responses. The full range of 
responses are provided in Additional file 2.
Box  2 A selection of  free text responses to  the ques-
tion: “What has surprised you most about  developments 
in malaria research in the last 20 years?”
“The limited progress made in developing a truly effective malaria vac‑
cine”. (other professional affiliation, high‑income country)
“The continued investments in vaccines and genomic solutions at the 
expenses of investments in vector control which have saved more 
children (than) any other intervention in the present and the previous 
malaria elimination campaigns” (Academia, high‑income country)
“That operational research is not more important” (Academia, high‑
income country)
“Low interest and lack of funding in malaria compared to new diseases 
such as HIV, few innovations in new effective malaria control tools” 
(National government, low‑income country)
“The unprecedented rise in the investment in malaria research in malaria 
endemic countries largely due to support from external funders. 
Despite this global effort how relatively little domestic funding gov‑
ernment in malaria endemic countries continue to invest in malaria 
research” (Academia, low‑income country)
“After working for 30 years on malaria control in Africa I was amazed 
when malaria started to decline in many African countries” (Academia, 
high‑income country)
51.7% 55.1%
13.3%
16.3%
21.7%
22.4%
13.3%
6.1%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Round 1 (N=60) Round 2 (N=49)
Not stated
Low income country
Middle income country
High income country
Fig. 3 Place of residence of participants
55.0% 57.1%
25.0%
28.6%
6.7%
8.2%13.3%
6.1%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Round 1 (N=60) Round 2 (N=49)
Not stated
Less than 10 years
Between 10 and 20 years
More than 20 years
Fig. 4 Years of relevant work experience of participants
Rank Round 1 
(% of total free text menons)
(n=170)
Rank Round 2
(% of respondents indicang issue as “most important”)
(n=48 respondents)
1 The development of new drugs for malaria 29.3% 1 The development of new drugs for malaria 75.0%
2 Inseccide treated nets and broader vector 
control research
28.6% 2 Increased funding for malaria intervenons 62.5%
3 Rapid diagnosc tests 12.9% 3 Inseccide-treated nets and broader vector 
control research
60.4%
4 Development of a malaria vaccine 5.4% 4 Rapid diagnosc tests 41.7%
5 Increased funding for malaria intervenons 5.4% 5 Idenficaon of resistance to artemisinin 
drugs in Southeast Asia
33.3%
6 Malaria informaon systems, surveillance 
and epidemiology
5.4% 6 Malaria informaon systems, surveillance
and epidemiology
20.8%
7 Policy/health system related research 4.8% 7 Development of a malaria vaccine 12.5%
8 Beer knowledge of the molecular biology 
and other basic science
4.1% 8 Policy/health system related research 10.4%
9 Seasonal malaria control 2.0% 9 Seasonal malaria control 4.2%
10 Idenficaon of resistance to artemisinin 
drugs in Southeast Asia
2.0% 10 Beer knowledge of the molecular biology 
and other basic science
2.1%
Note: The quesons and therefore denominators in each round are different. In the first round respondents were asked to name three top issues. These 
were collated and ranked. In the second round, the top ten issues were then represented to respondents and they were asked to indicate the importance 
of each issue on a five-point scale. 
The coloured arrows refer to movements in relave ranking. Green-up; Red-down; Blue – no change.
Fig. 5 Ranked most important past developments in malaria research
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“Most surprising has been that lack of “true innovation” in malaria com‑
munity. Our current best tools are still also our oldest” (Non‑govern‑
ment organization, low‑income country)
“The enormous disparity between research and policy, and the parallel 
universes of the research and international health/donor communities” 
(Academia, low‑income country)
“The little investments in health systems research—understanding how 
health systems could improve effective coverage of malaria interven‑
tions” (Academia, high‑income country)
“The slow progress from research into policy following the discovery of 
ACT while there was evidence that chloroquine resistance was associ‑
ated with increased mortality” (Academia, middle‑income country)
Views on priority areas for malaria research investment 
in the next 20 years
The next question asked experts to identify the prior-
ity areas for malaria research investment in the next two 
decades. In the first round experts were invited to sug-
gest up to three areas for priority investment. The results 
were collated and the top ten suggestions were presented 
back to participants in the second round as a ranked list of 
possible research investments. In the second round new 
and improved drugs was identified by 77.1% of the panel 
as the most important area for future research investment 
followed by vector control and the development of new 
insecticides (60.4% citing it as most important) (Fig.  6). 
Tackling drug resistance was ranked the third most 
important issue with 56.3% of participants citing it as 
‘most important’. Although investment in research capac-
ity building was only the tenth most frequently mentioned 
issue in the first round, it was promoted to the fourth 
most important area for investment in the second round.
Views on global health issues in the next 20–50 years
This next section asked experts to consider wider issues 
in global health in a longer timeframe. Here, there were 
notable differences between responses in rounds 1 and 
2. The first round asked experts to identify the three 
most important issues for global health in the next 
20–50 years. Non-communicable diseases (NCDs) in its 
various forms was the most frequently mentioned issue 
in the first round but dropped to seventh place when pre-
sented back to participants in the second round (Fig. 7). 
Tackling drug and insecticide resistance emerged as the 
biggest issue in the second round with 70.2% of experts 
citing it as ‘most important’ followed by improving access 
to health (58.3%) and completing the elimination agenda 
for existing communicable diseases (54.2%). Participants 
(in the first round only) were also asked what issue of 
global health importance today would be less important 
in the future. The top three issues were dominated by 
communicable diseases (Table 1).
Views on the importance of different research outcomes
The last question addressed expert views on the rela-
tive value or importance of different types of research 
outcomes and provided an opportunity to critique the 
five pre-determined payback framework categories. The 
Rank Round 1
(% of total free text menons)
(n=152)
Rank Round 2 
(% indicang issue as 'most important')
(n=48)
1 Vector control and development of new 
inseccides 
23.0% 1 New and improved drugs 77.1%
2 New and improved drugs 20.4% 2 Vector control and development of new 
inseccides
60.4%
3 Health policy and systems and operaonal 
research
9.2% 3 Tackling drug resistance 56.3%
4 Development of vaccines 8.6% 4 Local capacity building and training 43.8%
5 Tackling drug resistance 6.6% 5 Health policy and systems and operaonal 
research
20.8%
6 Malaria informaon systems, surveillance 
and epidemiology
5.3% 6 Malaria informaon systems, surveillance 
and epidemiology
18.8%
7 Improvement in diagnoscs 3.9% 7 Improvement in diagnoscs 14.9%
8 Research into changing transmission 3.9% 8 Development of vaccines 14.6%
9 Eliminaon research 3.3% 9 Eliminaon research 14.6%
10 Local capacity building and training 2.6% 10 Research into changing transmission 12.5%
Fig. 6 Ranked priority areas for malaria research investment in the next 20 years
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categories ‘informing policy and product development’ 
and ‘health and health sector benefit’ were weighted the 
highest in the first round with very similar mean values 
(25.4 and 25.6%, respectively) (Table  2). ‘Broader eco-
nomic benefits’ were considered the least important cate-
gory (12.9%). In the second round, the first round results 
(rounded to the nearest whole number) were presented 
to experts and asked whether they broadly agreed with 
the average weightings from the panel or whether they 
wished to adjust the results. Respondents were also asked 
whether they were broadly content with the payback 
framework as a system for classifying research outcomes.
The results in the second round were similar to those 
in the first, with the majority of respondents (78%) 
agreeing with the average weights presented from the 
earlier round. Those that disagreed were invited to sub-
mit revised weights. The impact of the revised weights 
was to slightly decrease the weight given to ‘contribu-
tion to knowledge’ and ‘benefits to future research’ and 
increase the weight to ‘health and health sector benefits’ 
and ‘broader economic benefits’ (see Table  2). However 
‘informing policy and product development’ and ‘health 
and health sector benefits’ remained the highest weighted 
research outcomes in round 2 with very similar mean val-
ues to those reported in round 1 (25.4 and 26.3%).
Analysis by background and location offered some 
insights as to how different groups might weight differ-
ent research outcomes, although a much bigger sample 
size would be needed to reveal significant differences. 
Those working in academic institutions on average gave 
a higher weight to ‘contribution to knowledge’ than 
those working in government or NGOs (see Additional 
file 3). However, all professional groups gave their highest 
average weighting to ‘health and health sector benefits’. 
Those working in high and middle income settings were 
more likely to give the highest weight ‘to informing pol-
icy and product development’ while those working in 
lower income settings weighted ‘health and health sector 
benefits’ the highest. In terms of number of years of rel-
evant experience (i.e., fewer than ten years; between ten 
and 20  years; and more than 20  years), all three groups 
weighted ‘health and health sector benefits’ the highest. 
That said, it is important to reiterate that the purpose of 
the Delphi was not to provide a quantitative analysis of 
these differences, but rather to gain the group’s overall 
judgement on the relative weight of each research out-
come category.
Most respondents (66.6%) were content with the way 
in which research outcomes were classified according to 
the payback framework. Of those that provided sugges-
tions for refinement, several suggested categories that 
were already captured in the framework, such as benefits 
to research capacity building (six respondents) or eco-
nomic benefits (two respondents). Suggestions for new 
research outcome categories not already captured by the 
payback framework, included ‘environment benefits’ (two 
respondents), ‘benefits for sustainability’ (one respond-
ent) and ‘elevating awareness of public health problems’ 
(one respondent). However, as the numbers suggesting 
changes were small, the research outcome classification 
system was left unchanged for the second round.
Discussion
Methods
On the basis of the response rate and comments, the 
Delphi method and the online survey approach were 
Rank Round 1 
(% menoning as important issue)
(n=152 menons)
Rank Round 2 
(% indicang issue as 'most important')
(n=48)
1 Tackling non-communicable diseases 22.4% 1 Tackling drug and inseccide resistance 70.2%
2 Compleng the eliminaon agenda for exisng 
communicable diseases (e.g., malaria, HIV, TB)
13.0% 2 Improving access to health care 58.3%
3 Tackling drug and inseccide resistance 11.2% 3 Compleng the eliminaon agenda for exisng 
communicable diseases (e.g., malaria, HIV, TB)
54.2%
4 Tackling emerging infecous diseases and global 
health security
8.7% 4 Tackling emerging infecous diseases and global health 
security
39.6%
5 Improving access to health care 6.2% 5 Global health financing 31.3%
6 Global health governance 4.3% 6 Maternal and newborn health 31.3%
7 Global health financing 3.1% 7 Tackling non-communicable diseases 21.3%
8 Climate change and the environment 5.0% 8 Climate change and the environment 19.1%
9 Delivering health care in urban sengs 2.5% 9 Global health governance 14.6%
10 Maternal and newborn health 2.5% 10 Delivering health care in urban sengs 6.4%
Fig. 7 Ranked most important global health issues in the next 20–50 years
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generally well received. Experts were willing to devote 
time and effort to complete two online surveys over five 
months and also provided helpful comments. Several 
researchers commented that it was good to have the 
opportunity to participate in a transparent approach to 
priority setting. The literature recommends anything 
from 10 to 80 experts on a Delphi panel [9, 11] and the 
study response rates compare favourably with other 
recent online Delphi surveys. For instance, an expert 
online Delphi survey on research and development into 
drugs for neglected diseases reported first and second 
round response rates of 30% (117/388) and 14% (56/388), 
respectively [14]. The sample selection was purposive in 
that it identified interested experts from specific sources, 
such as global malaria initiatives, review committees, 
conference presentations, and relevant publications. 
There was no notable difference in demographic char-
acteristics of participants between the two rounds. Both 
the first and second round samples were biased towards 
those working in academia and more than half stated 
their place of residence in a high-income country. As 
with other Delphi studies, it is impossible to judge how 
and if the results may have differed if the panel charac-
teristics were different [14]. There was some attrition in 
the response rates over the two rounds, with 11 partici-
pants dropping out between the first and second survey. 
However, as the characteristics of those completing both 
surveys were broadly similar it is unlikely that drops-outs 
overly influenced the nature of responses.
There are several strengths in the Delphi method as a 
structured process for gathering opinions. First, it ena-
bles input from individuals using a systematic anony-
mous and iterative approach to gain consensus on an area 
of interest. This is likely to allow a more inclusive process 
of determining values than focus group discussions [10]. 
Delphi surveys also allows for a range of individuals to 
express their opinion which can then be reassessed by 
considering the input from other participants, with the 
eventual aim of reaching some convergence [15]. A sig-
nificant advantage of the Delphi is that participants are 
very much aware at each stage of the results of the pre-
vious survey rounds, and there is scope for each panel 
member to provide more detailed feedback on both the 
process and the results.
Table 1 In your opinion, what issues of global health importance today will be less important in the future?
Question asked in round 1 only
Description No. of mentions (n = 44) %
Communicable diseases and the ‘classical infections’ 16 36
Neglected tropical diseases 5 11
HIV management 4 9
Diseases related to hygiene and sanitation, such as cholera 2 5
New emerging diseases 2 5
Inequities 1 2
Vaccines aimed at reducing mortality rather than interrupting or eliminating transmission 1 2
Car accidents 1 2
Famines 1 2
Fundamental studies of immunology, vaccinology and transgenics 1 2
Cancer and obesity 1 2
Commodity procurement 1 2
Don’t know 8 18
Table 2 What percentage weight would you give to  each of  the following  outcome categories, in  terms of  their impor-
tance to overall research impact?
Research outcome category Round 1 (n = 54) Round 2 (n = 49)
Mean value Std. err. Mean value Std. err.
Contribution to knowledge 19.6 2.47 18.9 0.53
Benefits to future research and research use 17.3 1.06 16.6 0.43
Benefits from informing policy and product development 25.4 1.56 25.4 0.26
Health and health sector benefits 25.6 1.45 26.3 0.40
Broader economic benefits 12.0 1.04 12.9 0.42
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While the Delphi method has several appealing char-
acteristics, there are limitations. First, the approach, as 
noted earlier, is not designed to be statistically repre-
sentative. Therefore, it is not possible to generalize these 
findings to the population of malaria research experts 
or researchers in general. Other more quantitative tech-
niques, such as discrete choice experiments, offer a way 
to systematically assess how groups value different types 
of research outcomes, although they are time consuming, 
require a lot of data and can be expensive to undertake. 
A second drawback of the Delphi approach is it can be 
a lengthy process due to its iterative nature. Linked to 
that, the multiple feedback processes, integral to the Del-
phi concept, mean the problem of low response rates are 
magnified. If a certain group of experts discontinue their 
responses during various stages of the Delphi process, the 
quality and reliability of the information obtained could 
be threatened [10]. A potentially more serious issue is 
that the iteration characteristics of the Delphi technique 
can potentially enable investigators to ‘mould’ opinions. 
One experiment conducted in the 1970s by Scheibe and 
colleagues showed that Delphi subjects would rate their 
responses differently after receiving distorted feedback 
[24]. So-called ‘acquiescence’ bias is a particular risk 
when asking respondents whether they agree with the 
presented findings from the first round.
A further drawback is an assumption that Delphi partic-
ipants “are equivalent in knowledge and experience” [25]. 
There are good reasons for concern that the knowledge of 
participants could be unevenly distributed, whereby some 
participants have much more expertise in certain areas 
than others. Experts who have less in-depth knowledge 
of certain topics may be unable to distinguish the most 
important statements that have been identified by those 
subjects who possess wider knowledge. In these instances 
the outcomes of a Delphi study could be the result of iden-
tifying a series of ‘general’ issues rather than an in-depth 
exploration of the topic. While this is certainly a risk, it is 
arguably a risk for all qualitative investigations that seek to 
gather some kind of group consensus. None of the issues 
or questions raised by the Delphi were thought to beyond 
the expertise of any of the participating experts.
Another potential criticism of the study approach is 
that the final sample was biased towards research experts 
largely working in academic institutions. It is acknowl-
edged that malaria research, particularly operational 
research, is also conducted outside of traditional aca-
demic settings, such as in non-governmental organiza-
tions or other implementing agencies. It could be the case 
that a sample with a more diverse background could have 
led to different results, such as an even higher weight-
ing on later stage impact. Future work could explore the 
views of those working in other settings.
The dominance by northern academics based in high-
income countries means there may be a bias in the round 
1 free text mentions that was propagated to round 2, 
given the structure of the iterative process. On reflection 
more information on the areas of particular interest of 
panel members could have been requested. However, it 
might have been hard for experts to narrowly define their 
interests. It is also likely that many panel members had 
overlapping interests, making interpretation difficult.
Research priorities
The study highlighted the importance of past research 
developments in malaria, particularly the development of 
new drugs, insecticide-treated bed nets and broader vec-
tor control. However, experts were also keen to highlight 
that increased funding for malaria interventions more 
generally were critical to improvements in the scientific 
knowledge base. Priorities for future malaria research 
investment reflected areas where the most success had 
been seen in the past (vector control and new drugs), 
but also highlighted the importance of tackling emerg-
ing drug and insecticide resistance, in particular resist-
ance to artemisinin-based combination therapy. Experts 
agreed that staying ahead of the challenge of resistance 
requires expanding the pipeline of new drugs, diagnostics 
and other tools. One participant commented that there 
has been a lack of “true innovation” in the community, 
arguing that “our current best tools are still also our old-
est”. Local capacity building and wider health systems and 
operational research were also highlighted. This possibly 
reflects a more general concern that there is a potential 
‘disconnect’ between researchers and implementers and 
there are insufficient people with the skills to bridge this 
gap. One expert commented that funders are more will-
ing to fund the clinical science with less supporting oper-
ational or implementation research.
Looking beyond malaria, experts identified tackling 
broader drug resistance (i.e., antimicrobial and antibacte-
rial) as the most important area for attention in the next 
20–50 years. This reflects wider political and global con-
cern on the growing threat of resistance; both the UK and 
WHO have raised this issue as a global threat [26, 27]. 
The one case where there was apparently less congruence 
between the two rounds was on the importance of NCDs. 
NCDs was the most frequently mentioned future global 
issue in the first round, but participants ranked NCDs 
lower (seventh) in the second round when it was pre-
sented alongside other issues. Most obviously, this may 
reflect the disciplinary bias of the group, who all worked 
in infectious disease. But there is little doubt that chronic 
NCDs are reaching epidemic proportions worldwide 
[28]. NCDs currently make up more than 40% of the dis-
ease burden and are expected to overtake communicable 
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diseases as the major cause of mortality in low-income 
countries (LICs) by 2030 [29]. Indeed, the emergence 
of NCDs in LICs is partially the result of progress in 
tackling high-burden communicable diseases such as 
HIV/AIDs, tuberculosis and malaria with the resultant 
increase in average life expectancy in many countries 
[30]. However (to participants at least) it may be that the 
perception of the NCD burden in sub-Saharan Africa is 
still overshadowed by the unfinished agenda on commu-
nicable diseases as well as tackling emerging infectious 
diseases of epidemic potential, such as Ebola.
Valuing research outcomes
A key aim of the Delphi survey was to elicit expert views 
on the relative importance of different global health 
research outcomes. In this context ‘value’ is equated 
to percentage weight assigned to each outcome cate-
gory. The findings suggest that malaria research experts 
prioritized research outcomes that focused most on 
‘health and health sector benefits’ and ‘informing pol-
icy and product development’. The overall rankings did 
not change over the two rounds of the survey, although 
there were some differences within each round when 
the results were broken down by experience, region and 
employment sector. ‘Contribution to scientific knowl-
edge’ came lower down the priority list, suggesting that 
participating experts valued efforts to move research 
discoveries to health products and services over pure 
advances in scientific knowledge. Broader economic out-
comes were valued the least important. The finding that 
economic outcomes are weighted less highly than health 
outcomes is perhaps not that surprising. This is a simi-
lar finding to a previous study looking at the outcomes of 
medical research in Canada [8]. The authors suggest this 
could reflect researcher views on the limited potential of 
research to generate pure economic returns, but it could 
also reflect the lack of data on the economic returns of 
health research more generally, malaria research in par-
ticular. Similarly, a more recent study conducted in the 
UK suggested that: “achieving higher life expectancy for 
adults living with a common chronic disease in the UK 
is one of the highest priorities for the general public and 
researchers—well ahead of commercial and employ-
ment benefits (from the research)” [31]. That said, the 
same study found that researchers and the general public 
agreed that creating substantial numbers of jobs through 
research is important, suggesting that perceptions of eco-
nomic impact can be more nuanced. Exploring the eco-
nomic rates of return from global health research will be 
the subject of future work.
It is worth keeping in mind that the different outcomes 
from research are not mutually exclusive, and are often 
interlinked in a logic chain from a research award or 
grant, through to research outputs through to impact. A 
research programme that performs well on one dimen-
sion, for example building research capacity, may mean 
performing less well on another dimension, such as pub-
lishing high-impact journal articles. Nonetheless, the 
findings suggest that more value should be placed on 
later stage impact indicators with participants giving a 
combined weight of 36% to the two indicators (i.e., health 
and health sector benefits + broader economic benefits). 
This is higher than the impact weight of 20% assigned by 
the UK Research Excellence Framework [32]. A key ques-
tion, inevitably, is how to accurately identify, attribute 
and measure those impacts.
Conclusions
The Delphi process was found to be a reasonably 
straightforward approach for eliciting views on research 
priorities, particularly when compared to more intensive 
priority setting exercises, such as the Malaria Eradication 
Research Agenda (malERA), which over the course of two 
years involved more than 250 experts from 36 countries 
in 20 face-to-face meetings around the world [33]. While 
the approach certainly has limitations, it could be a use-
ful low-cost complement to these large-scale endeavours, 
particularly if undertaken on sub-topics within malaria.
The assessment of the wider impact of research is 
becoming a firmly established field. The UK in many ways 
has been at the forefront of efforts to take a more system-
atic approach to assessing impact by asking researchers 
to include four-page impact case studies in their submis-
sions to the 2014 Research Excellence Framework [34]. 
During this process, the research of 154 English higher 
education institutes was assessed and graded, with the 
results informing the allocation of around £1.6 billion of 
research funding [31]. This study shows that it is possi-
ble to arrive at a degree of consensus on the weight or 
value of different types of research outcome using the 
Delphi technique amongst a particular stakeholder group 
(malaria research experts). While there have been previ-
ous studies examining the relative valuations of different 
kinds of research impact [8, 31], this is the first study to 
consider global health research relevant to people liv-
ing in developing countries. Future work will explore 
the extent to which it is possible to develop a composite 
research performance indicator, by applying the weights 
derived in the study to a sample of research outputs to 
see whether it changes the rankings for the valuation 
of research more generally. However, a key issue is the 
extent to which different stakeholders might value differ-
ent research outcomes in different ways. As Pollitt et al. 
also note, this is vital to know as funders are actively 
encouraging research groups to take into account the 
wider benefits of research [31]. More work is needed 
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to validate and build upon these and previous findings, 
particularly for global health research. One possibility is 
to repeat the exercise with different stakeholder groups 
and/or consider the use of more quantitative techniques, 
such as discrete choice experiments, to derive more 
robust comparative estimates of relative value across a 
broader range of research beneficiaries. Nonetheless it is 
hoped the findings presented here will add to the global 
evidence base on how stakeholder views could, or should, 
influence judgements on the overall performance of pub-
lically funded global health research.
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